FierceBiotech2d
Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks, setting stage for pivotal program
Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...
Business Wire3d
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapav…
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
GlobalData on MSN14d
Magazine: Cell and gene therapy approvals drive paradigm change in manufacturing
The manufacturing shift to meet growing cell and gene therapy demand, applying lessons from the Covid-19 pandemic to address ...
Exelixis, Merck Sign Clinical Development Deal To Evaluate Zanzalintinib With KEYTRUDA, WELIREG
Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development ...
Merck RSV therapy cuts respiratory infections by 60% in infants
Merck’s (NYSE:MRK) monoclonal antibody clesrovimab, designed as a prophylactic against respiratory syncytial virus (RSV), has ...
GlobalData on MSN12d
Merck unveils $318m biosafety testing facility in Maryland, US
Germany-based Merck KGaA has announced the launch of a new €290m ($317.6m) biosafety testing facility in Rockville, Maryland, ...
Pharmabiz8d
Exelixis, Merck enter clinical development collaboration to evaluate zanzalintinib in combo with Keytruda in HNSCC and in combo with Welireg in RCC
Alameda, California Tuesday, October 15, 2024, 14:00 Hrs [IST] ...
GEN12d
MilliporeSigma Opens Glitzy $286 Million Biosafety Testing Facility in Maryland
Among the newer initiatives was developing the lab of the future; next-gen biology; AI and sustainability. The new facility ...
Targeted Oncology14d
Perioperative Pembrolizumab Betters Survival in Stage III/IV Head and Neck Cancer
The KEYNOTE-689 study evaluating pembrolizumab in this patient population met its primary end point of event-free survival.
Scoop6d
Merck Welcomes Funded Access To Cancer Treatment Erbitux® (Cetuximab)
From 1 November, a targeted cancer treatment will join the country’s Pharmaceutical Scheme for eligible New Zealanders diagnosed with a specific type of advanced bowel cancer. Globally recognised as a ...